One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma

Annals of Allergy, Asthma and Immunology

Volumn 89, Issue 2, 2002, Pages 180-190

  Bensch, George ^a   Berger, William E ^b   Blokhin, Boris M ^c   Socolovsky, Aron L ^d   Thomson, Moira H ^e   Till, M Denise ^e   Castellsague, Jordi ^f   Cioppa, Giovanni Della ^e  

^a Southern California Research Center ^*  (United States)

^b Southern California Research Center   (United States)

^c Children Polyclinic   (Russian Federation)

^d HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^e NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^f Global Epidemiology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL; FORMOTEROL FUMARATE; NEDOCROMIL SODIUM; SALBUTAMOL;

AIRFLOW; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; EARLY DIAGNOSIS; EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 0036706907     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61935-7     Document Type: Article

References (32)

1. National Asthma Education and Prevention Program Expert Panel. Expert Panel No 2: Guidelines to the Diagnosis and Management of Asthma. Bethesda, MD: National Institute of Health/National Heart and Blood Institute, 1997. NIH Publication no 97-4051.
2. British Asthma Guidelines Co-ordinating Committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52(Suppl):S1-S24.
3. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group. Eur Respir J 1994;7:63-68.
4. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-224.
5. Boyd G. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. Eur Respir J 1995;8:1494-1498.
6. Faurschou P, Steffensen I, Jacques L. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. Eur Respir J 1996;9:1885-1890.
7. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-1488.
8. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol And Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-1411.
9. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995;75:423-428.
10. Meijer GG, Postma DS, Mulder PG, van Aalderen WM. Longterm circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Am J Respir Crit Care Med 1995; 152:1887-1892.
11. Weinstein SF, Pearlman DS, Bronsky EA, et al. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. Ann Allergy Asthma Immunol 1998;81:51-58.
12. Lenney W, Pedersen S, Boner AL, et al. Efficacy and safety of salmeterol in childhood asthma. Eur J Pediatr 1995;154: 983-990.
13. von Berg A, de Blic J, la Rosa M, et al. A comparison of regular salmeterol vs 'as required' salbutamol therapy in asthmatic children. Respir Med 1998;92:292-299.
14. Zarkovic J, Goetz MH, Holgate ST, Taak NK. Effect of longterm regular salmeterol treatment in children with moderate asthma. Clin Drug Invest 1998;15:169-175.
15. American Thoracic Society (American Lung Association). Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-244.
16. Van Elteren PH. On the combination of independent twosample tests of Wilcoxon. Bull Int Stat Inst 1960;37:351-361.
17. US Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-94, Reference manuals and reports. Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
18. Owings MF, Lawrence L. Detailed diagnosis and procedures. National Hospital Discharge Survey, 1997. National Center for Health Statistics. Vital Health Stat 13(145), 1999.
19. Enright PL, Lebowitz MD, Cockcroft DW. Physiologic measures: pulmonary function tests. Am J Respir Crit Care Med 1994;149:S9-S18.
20. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968;278:1355-1360.
21. Burrows B. Course and prognosis of patients with chronic airways obstruction. Chest 1980;77:250-251.
22. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108:1235-1239.
23. 2 agonists. Is there cause for concern? Drug Saf 1997;16:295-308.
24. FitzGerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J Allergy Clin Immunol 1999;103:427-435.
25. Hui KK, Connoly ME, Tashkin DP. Reversal of human lymphocyte β-adrenoceptor desensitization by glucocorticoids. Clin Pharmacol Ther 1982;32:566-571.
26. Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-695.
27. Wang X, Dockery D, Wypil D, et al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15: 75-88.
28. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-930.
29. Kips JC, O'Connor BJ, Inman MD, et al. A long-term study on the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000;161:996-1001.
30. Verberne AA, Frost C, Duiverman EJ, et al. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998;158:213-219.
31. FDA Talk Paper. FDA requires new pediatric labeling for inhaled, intranasal corticosteroids. Rockville, MD: FDA, 1998.
32. Medicines Control Agency. The safety of inhaled and nasal corticosteroids. Curr Probl Pharmacovigilance 1998;24:5-10.